Cardiovascular pharmacologic therapies under investigation: 2012

Cardiology in Review

Volumn 20, Issue 3, 2012, Pages 102-110

  Frishman, William H ^a   Pallerla, Kalyana ^b  

^a WESTCHESTER MEDICAL CENTER   (United States)

^b Mount Vernon Hospital USA   (United States)

Author keywords

antisense drugs; gene therapy; innovative pharmacology; new cardiac treatments

Indexed keywords

2 [4 (2,5 DIFLUOROBENZYLOXY)PHENOXY] 5 ETHOXYANILINE; 2 [4 [3 [4,5 DIHYDRO 1 (4 METHYLBENZYL) 5 OXO 1H 1,2,4 TRIAZOL 3 YL]PROPYL]PHENOXY] 2 METHYLPROPIONIC ACID; 4 [3 (4 BENZYL 1 PIPERIDINYL)PROPIONYL] 2,3,4,5 TETRAHYDRO 7 METHOXY 1,4 BENZOTHIAZEPINE; ABCIXIMAB; AC 2592; ACT 280778; ADOMIPARIN; ADX 415; AEGR 427; AG 1067; ALAGEBRIUM; ALBIGLUTIDE; ALISKIREN; AMIODARONE; AMR 001; AMR 101; ANACETRAPIB; ANGX 1039; ANIVAMERSEN; ANTICOAGULANT AGENT; ANTITHROMBOCYTIC AGENT; APD 8111; APIXABAN; AR 9281; ARC 791; AT 2042; ATACIGUAT; ATOPAXAR; ATRELEUTON; ATRIAL NATRIURETIC FACTOR ALPHA; AVE 5530; AZD 1305; AZILSARTAN MEDOXOMIL; AZIMILIDE; BI 204; BMS 394136; BUCINDOLOL; BUDIODARONE; CAPADENOSON; CARVEDILOL; CELIVARONE; CER 001; CER 002; CER 627; CINACIGUAT; CLONIBID; CLONIDINE; CP 800569; CSL 112; CV 10153; DABIGATRAN ETEXILATE; DALCETRAPIB; DANEGAPTIDE; DARAPLADIB; DAREXABAN; DELCASERTIB; DIAPLASININ; DROSPIRENONE PLUS ESTRADIOL; EDOXABAN; EGAPTIVON PEGOL; ELINOGREL; EPTIFIBATIDE; ETC 1002; ETC 216; EVACETRAPIB; FASUDIL; FONDAPARINUX; GS 9667; GSK 256073; HIRULOG; IK 5001; IMATINIB; IRBESARTAN; ISTAROXIME; IVABRADINE; K 134; K 604; LCI 1699; LCQ 908; LCZ 696; LETAXABAN; LOMITAPIDE; LOSMAPIMOD; MBX 8025; MD 0727; MER 102; MIPOMERSEN; MK 0524B; MLN 1202; MOPERONE; MPC 028; MPC 0920; MZ 004; N [2 [4 (1 METHYL 4 PIPERIDINYL) 1 PIPERAZINYL] 2 OXO 1 PHENYLETHYL] 1H INDOLE 6 CARBOXAMIDE; NAXIFYLLINE; NCX 899; NELOCIGUAT; NEU 2000; NIFEKALANT; NOVEL ERYTHROPOIESIS STIMULATING PROTEIN; NTC 801; NU 172; OMECAMTIV MECARBIL; OMEGA 3 FATTY ACID ESTER; OTAMIXABAN; PAROGRELIL; PCI 27483; PEGMUSIRUDIN; PEGNIVACOGIN; PF 04950615; PL 3994; PRAVEFEN; PRX 08066; PS 433540; PSI 697; PVS 10200; RG 1512; RG 7232; RIFALAZIL; RILAPLADIB; RIVAROXABAN; RVX 208; SAR 236553; SAR 407899; SARPOGRELATE; SEMATILIDE; SEMULOPARIN; SILDENAFIL; SIMVASTATIN PLUS SITAGLIPTIN; SITAXSENTAN; SLV 320; SLX 4090; SOBETIROME; SPI 017; TECADENOSON; TECARFARIN; TEMANOGREL; TERUTROBAN; TICAGRELOR; TRIA 662; TTP 3389; UNCLASSIFIED DRUG; UNINDEXED DRUG; UNIPROST; UROCORTIN III; VARESPLADIB; VELITRI; VERNAKALANT; VM 202; VORAPAXAR; VTP 27999; WAY 197697; XRP 0038;

ANGINA PECTORIS; ATHEROSCLEROSIS; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CLINICAL TRIAL (TOPIC); DIABETES MELLITUS; DRUG ELUTING STENT; DRUG MECHANISM; HEART ARRHYTHMIA; HEART ATRIUM FIBRILLATION; HEART FAILURE; HEART INFARCTION; HEART MUSCLE ISCHEMIA; HUMAN; HYPERTENSION; OBESITY; PERIPHERAL VASCULAR DISEASE; PULMONARY HYPERTENSION; REVIEW; RISK REDUCTION; STROKE; TREATMENT INDICATION; VENOUS THROMBOEMBOLISM;

CARDIOVASCULAR AGENTS; CARDIOVASCULAR DISEASES; DRUGS, INVESTIGATIONAL; GENE THERAPY; HUMANS; STEM CELL TRANSPLANTATION; THERAPIES, INVESTIGATIONAL; VACCINES;

EID: 84859631487     PISSN: 10615377     EISSN: 15384683     Source Type: Journal    
DOI: 10.1097/CRD.0b013e31824c8504     Document Type: Review

References (38)

1. Braunwald E. Adventures in cardiovascular research. Circulation. 2009; 120:170-180.
2. Frishman WH. The patient-physician-industry-government partnership: a societal good. Am J Med. 2009;122:886-887.
3. Alfonso F, Fernandez C. Second-generation drug-eluting stents. J Am Coll Cardiol. 2011;58:26-29.
4. Ormiston JA, Webber B, Webster MWI. Stent longitudinal integrity. Bench insights into a clinical problem. J Am Coll Cardiol Cardiovasc Intervent. 2011;4:1310-1317.
5. Medicines in Development for Heart Disease and Stroke, 2009 Report. Presented by America's Pharmaceutical Research Companies. Billy Tauzin, President and CEO, PhRMA.
6. Leri A, Anversa P, Frishman WH. Cardiovascular Regeneration and Stem Cell Therapy. UK: Blackwell/Futura 2007.
7. Sakhuja R, Yeh RW, Bhatt DL. Antiplatelet agents in acute coronary syndromes. Curr Probl Cardiol. 2010;35:123-170.
8. Zeidner JF, Frishman WH, Lerner RG. Investigational antiplatelet drugs for the treatment and prevention of coronary artery disease. Cardiol Rev. 2008;16:250-259.
9. Gross PL, Weitz JI. New antithrombotic drugs. Clin Pharmacol Ther. 2009;86:139-146.
10. Rao SV, Melloni C, Myles-Dimauro S, et al.; EMINENCE Investigators. Evaluation of a new heparin agent in percutaneous coronary intervention: results of the phase 2 evaluation of M118 IN pErcutaNeous Coronary intErvention (EMINENCE) Trial. Circulation. 2010;121:1713-1721.
11. Tian D, Frishman WH. Vernakalant: a new drug to treat patients with acute onset atrial fibrillation. Cardiol Rev. 2011;19:41-44.
12. Kowey PR, Crijns HJGM, Aliot EM, et al on behalf of the ALPHEE Study Investigators. Efficacy and safety of celivarone, with amiodarone as calibrator, in patients with implantable cardioverter-defibrillator for prevention of implantable cardioverter-defibrillator interventions or death. The ALPHEE study. Circulation. 2011;124:2649-2660.
13. Khakpour H, Frishman WH. Lipoprotein-associated phospholipase A2: an independent predictor of cardiovascular risk and a novel target for immunomodulation therapy. Cardiol Rev. 2009;17:222-229.
14. Džavík V, Lavi S, Thorpe K, et al. The sPLA2 Inhibition to Decrease Enzyme Release after Percutaneous Coronary Intervention (SPIDER-PCI) trial. Circulation. 2010;122:2411-2418.
15. Parikh N, Frishman WH. Liver x receptors: a potential therapeutic target for modulating the atherosclerotic process. Cardiol Rev. 2010;18:269-274.
16. Erickson B, Sperber K, Frishman WH. Toll-like receptors: new therapeutic targets for the treatment of atherosclerosis, acute coronary syndromes, and myocardial failure. Cardiol Rev. 2008;16:273-279.
17. Peterson SJ, Frishman WH, Abraham NG. Targeting heme oxygenase: therapeutic implications for diseases of the cardiovascular system. Cardiol Rev. 2009;17:99-111.
18. Sherman CB, Peterson SJ, Frishman WH. Apolipoprotein A-I mimetic peptides: a potential new therapy for the prevention of atherosclerosis. Cardiol Rev. 2010;18:141-147.
19. Barkowski RS, Frishman WH. HDL metabolism and CETP inhibition. Cardiol Rev. 2008;16:154-162. (Pubitemid 351549677)
20. Ladenson PW, Kristensen JD, Ridgway EC, et al. Use of the thyroid hormone analogue eprotirome in statin-treated dyslipidemia. N Engl J Med. 2010;362:906-916.
21. Ricotta DN, Frishman WH. Mipomersen: a safe and effective antisense therapy adjunct to statins in patients with hypercholesterolemia. Cardiol in Rev. 2012;20:90-95.
22. Raal FJ, Santos RD, Blom DJ, et al. Mipomersen, an apolipoprotein B synthesis inhibitor, for lowering of LDL cholesterol concentrations in patients with homozygous familial hypercholesterolaemia: a randomised, double-blind, placebo-controlled trial. Lancet. 2010;375:998-1006.
23. Oghlakian G, Klapholz M. Vasopressin and vasopressin receptor antagonists in heart failure. Cardiol Rev. 2009;17:10-15.
24. Grossman J, Frishman WH. Relaxin: a new approach for the treatment of acute congestive heart failure. Cardiol Rev. 2010;18:305-312.
25. Metra M, Teerlink JR, Felker GM, et al. Dyspnoea and worsening heart failure in patients with acute heart failure: results from the Pre-RELAX-AHF study. Eur J Heart Fail. 2010;12:1130-1139.
26. Shah RH, Frishman WH. Adenosine1 receptor antagonism: a new therapeutic approach for the treatment of decompensated heart failure. Cardiol Rev. 2009;17:125-131.
27. Peterman C, Sanoski CA. Tecadenoson: a novel, selective A1 adenosine receptor agonist. Cardiol Rev. 2005;13:315-321. (Pubitemid 41579598)
28. Teerlink JR, Clarke CP, Saikali KG, et al. Dose-dependent augmentation of cardiac systolic function with the selective cardiac myosin activator, omecamtiv mecarbil: a first-in-man study. Lancet. 2011;378:667-675.
29. Povsic TJ, O'Connor CM, Henry T, et al. A double-blind, randomized, controlled, multicenter study to assess the safety and cardiovascular effects of skeletal myoblast implantation by catheter delivery in patients with chronic heart failure after myocardial infarction. Am Heart J. 2011;162:654-662.e1.
30. Bolli R, Chugh AR, D'Amario D, et al. Cardiac stem cells in patients with ischaemic cardiomyopathy (SCIPIO): initial results of a randomised phase 1 trial. Lancet. 2011;378:1847-1857.
31. Metra M, Bettari L, Carubelli V, et al. Use of inotropic agents in patients with advanced heart failure: lessons from recent trials and hopes for new agents. Drugs. 2011;71:515-525.
32. Riley E, Dasari V, Frishman WH, et al. Vaccines in development to prevent and treat atherosclerotic disease. Cardiol Rev. 2008;16:288-300.
33. Prasad VS, Palaniswamy C, Frishman WH. Endothelin as a clinical target in the treatment of systemic hypertension. Cardiol Rev. 2009;17:181-191.
34. Ruilope LM, Dukat A, Böhm M, et al. Blood-pressure reduction with LCZ696, a novel dual-acting inhibitor of the angiotensin II receptor and neprilysin: a randomised, double-blind, placebo-controlled, active comparator study. Lancet. 2010;375:1255-1266.
35. Waeber B, Feihl F. Blood-pressure reduction with LCZ696. Lancet. 2010;375:1228-1229.
36. Hingorany S, Frishman WH. Soluble guanylate cyclase activation: New discoveries in the treatment of decompensated heart failure. Cardiol in Rev. 2011;19:23-29.
37. Mandal K, Jahangiri M, Xu Q. Progenitor cells and vascular repair. In: Leri A, Anversa P, Frishman WH, eds. Cardiovascular Regeneration and Stem Cell Therapy. UK: Blackwell/Futura; 2007:57.
38. Frishman WH, Pallerla K. Cardiovascular drugs in development. In: Frishman WH, Sica DA, eds. Cardiovascular Pharmacotherapeutics. 3rd ed. Minneapolis, MN: Cardiotext; 2011:619-630.